Biovie Inc (BIVI) - Total Assets
Based on the latest financial reports, Biovie Inc (BIVI) holds total assets worth $17.51 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Biovie Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Biovie Inc - Total Assets Trend (2013–2025)
This chart illustrates how Biovie Inc's total assets have evolved over time, based on quarterly financial data. See BIVI net assets for net asset value and shareholders' equity analysis.
Biovie Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Biovie Inc's total assets of $17.51 Million consist of 96.0% current assets and 4.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.4% |
| Accounts Receivable | $2.10 Million | 9.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $178.34K | 0.8% |
| Goodwill | $345.71K | 1.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Biovie Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIVI market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biovie Inc's current assets represent 96.0% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 81.4% of total assets in 2025, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 9.8% of total assets.
Biovie Inc Competitors by Total Assets
Key competitors of Biovie Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Biovie Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.97 | 9.32 | 4.62 |
| Quick Ratio | 9.97 | 9.32 | 4.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.19 Million | $21.17 Million | $3.61 Million |
Biovie Inc - Advanced Valuation Insights
This section examines the relationship between Biovie Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.80 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | -14.5% |
| Total Assets | $21.56 Million |
| Market Capitalization | $11.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biovie Inc's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biovie Inc's assets decreased by 14.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biovie Inc (2013–2025)
The table below shows the annual total assets of Biovie Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $21.56 Million | -14.46% |
| 2024-06-30 | $25.21 Million | -28.19% |
| 2023-06-30 | $35.10 Million | +74.52% |
| 2022-06-30 | $20.11 Million | +232.65% |
| 2021-06-30 | $6.05 Million | +190.16% |
| 2020-06-30 | $2.08 Million | -19.05% |
| 2019-06-30 | $2.57 Million | +18.34% |
| 2018-06-30 | $2.18 Million | -7.98% |
| 2017-06-30 | $2.36 Million | -13.05% |
| 2016-06-30 | $2.72 Million | +909.04% |
| 2015-06-30 | $269.48K | -19.04% |
| 2014-06-30 | $332.86K | -34.18% |
| 2013-06-30 | $505.70K | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more